Table 1.
Virological response in HDV patients treated with pegIFNα, BLV with or without pegIFNα, pegIFNλ, and LNF+RTV with or without pegIFNα
| Treatment strategies | No of patients | HDV RNA levels (log IU/ml) | Duration of therapy (weeks) |
Virological response | ||||||||
| HDV RNA <LLoQ | HDV RNA: >2 log IU/mL decline or <LLoQ | HDV RNA decline (mean or median log IU/mL) |
||||||||||
| Baseline | During therapy | Off-therapy | During therapy | Off-therapy | During therapy | Off-therapy | ||||||
| Week 24 | Week 48 | Week 24 | Week 24 | Week 48 | Week 24 | Week 24 | Week 48 | Week 24 | ||||
| PegIFNα 180 μg QW* | 15 | 5.44 | 48 | – | 13.3% | 0% | – | – | 0% | – | −1.29 | −0.26 |
| BLV 2 mg every day mono* | 15 | 6.39 | 48 | 13% | 13.3% | 6.7% | – | – | 33.3% | – | −2.84 | −1.08 |
| BLV 10 mg every day mono* | 15 | 5.6 | 48 | 27% | 40% | 33.3% | – | – | 46.7% | – | −4.58 | – |
| BLV 2 mg every day +pegIFNα 180 μg QW* | 15 | 5.48 | 48 | 67% | 80% | 53.3% | – | – | 73.3% | – | −5.21 | −4.04 |
| BLV 10 mg every day +pegIFNα 180 μg QW* | 15 | 5.9 | 48 | 60% | 86.7% | 6.7% | – | – | 33.3% | – | −6.09 | – |
| LNF 50 mg two times per day+RTV 100 mg two times per day† | 12 | – | 24 | 42% | – | – | 39% | – | – | −1.66 | – | – |
| LNF 50 mg two times per day+RTV 100 mg two times per day+pegIFNα 180 μg QW† | 4 | – | 24 | 50% | – | – | 89% | – | – | −3.71 | – | – |
| PegIFNλ 180 μg QW‡ | 14 | 3.86 | 48 | – | 36% | 36% | – | – | – | −2.72 | −2.3 | −1.86 |
| LNF 50 mg two times per day+RTV 100 mg two times per day+pegIFNλ 180 μg QW§ | 26 | 4.74 | 24 | 27% | – | 19% | 96% | – | – | −3.4 | – | – |
*MYR203 study, HDV RNA assay LLoQ 10 IU/mL.
†LOWR-2 study, Robogene assay, LLoQ 14 IU/mL.
‡LIMT study, Robogene assay, LLoQ 14 IU/mL.
§LIFT HDV study, Quest Diagnostics Assay, HDV RNA LLoQ <40 IU/mL or <1.6 log IU/ml; ‘-’: data not published or not presented.
BLV, bulevirtide; HDV, hepatitis D virus; LNF, lonafarnib; pegIFNα, pegylated interferon-α; RTV, ritonavir.